Comparative Study of the Clinical Characteristics of Patients With Sexually Transmitted Infections Diagnosed by Nucleic Acid Amplification Tests Authors: Jung Soo Son, Namhee Kim, Hong Sang Oh, Sang Won Park, Dong Hoon Shin Published: 2025 ABSTRACT AbstractBackgroundSexually transmitted infections (STIs) caused by Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), and Neisseria gonorrhoeae (NG) are major public health concerns. While nucleic acid amplification tests (NAATs) are the primary diagnostic tool for these pathogens, research on pathogen-specific characteristics and risk factors for NAAT clearance failure remain limited in Korea. This study analyzed clinical features of STIs and post-treatment NAAT changes.MethodsThis retrospective cohort study included adult, non-pregnant patients diagnosed with CT, MG, or NG via NAAT at a secondary care hospital between 2012 and 2024. Clinical characteristics were compared using the Kruskal-Wallis test, and multivariate logistic regression identified risk factors for NAAT clearance failure in patients with follow-up NAAT within three months.ResultsAmong 500 STI cases, 80.8% were female, with a median age of 27.0 years. CT was the most common pathogen (53.8%), followed by MG (37.2%) and NG (9.0%). CT infections had the highest complication rate (28.6%), while NG infections were more frequently symptomatic (77.8%) and associated with pyuria (46.4%). Of 221 patients with follow-up NAAT, 14.9% failed clearance. MG infection (adjusted odds ratio [aOR], 6.100; 95% confidence interval [CI], 2.711–13.725; P < 0.001) and symptomatic presentation (aOR, 2.542; 95% CI, 1.103–5.861; P = 0.029) were independent risk factors for clearance failure.ConclusionCT showed the highest complication rate and NG was the most symptomatic. MG was a key predictor of NAAT clearance failure, underscoring the need for antimicrobial resistance monitoring and optimized retreatment strategies.Keywords: Sexually Transmitted Infections, Nucleic Acid Amplification Tests, Chlamydia trachomatis, Mycoplasma genitalium, Neisseria gonorrhoeae INTRODUCTION Sexually transmitted infections (STIs) are a significant global public health issue. The global burden of STIs is substantial, with more than 1 million curable STIs acquired every day, according to the World Health Organization.1 A significant proportion of STIs are asymptomatic, resulting in an underestimation of reported cases and enabling transmission to occur unnoticed by affected individuals. If left untreated, STIs can lead to an increased risk of acquiring other infections—including human immunodeficiency virus (HIV)—and transmitting STIs to others.2 STIs are primarily caused by bacterial, viral, and parasitic pathogens, with bacterial STIs such as Chlamydia trachomatis (CT), Mycoplasma genitalium (MG), and Neisseria gonorrhoeae (NG) being prominent contributors to the disease burden.3 As of 2023, surveillance data in Korea show that HPV-related infections were the most commonly reported, followed by genital herpes, Chlamydia infections, and gonorrhea.4 Gonococcal urethritis remains prevalent; however, among the major pathogens causing non-gonococcal urethritis, CT is the most common. Additionally, MG has been reported to be detected in over 20% of symptomatic patients in Korea, raising concerns about its increasing prevalence.5 Among bacterial STI pathogens, Ureaplasma urealyticum, U. parvum, and Mycoplasma hominis are considered symbiotic bacteria, and their detection in specimen remains a topic of debate regarding clinical significance.6 However, infections caused by CT, MG, and NG have been reported to be associated with complications such as pelvic inflammatory disease, epididymitis, prostatitis, and infertility, even in non-pregnant patients, and are therefore regarded as pathogens requiring treatment.7,8 Accurate diagnosis and timely treatment are critical for managing STIs and preventing complications. Traditional diagnostic methods, such as culture, often lack sensitivity, especially for pathogens causing non-gonococcal infections, like CT and MG, which are difficult to cultivate in vitro.9 To overcome these limitations, nucleic acid amplification tests (NAATs) with high sensitivity and specificity have become the standard for diagnosing STIs.8,10,11 Notably, NAAT-based diagnosis does not provide information on antibiotic susceptibility, necessitating the use of empirical antibiotic therapy.6,8 Increasing antimicrobial resistance particularly in NG and MG, has become a significant challenge worldwide.12,13 Given the recent trends in resistance, strategies such as post-treatment follow-up NAAT to confirm microbial clearance might be considered.8 In Korea, however, there is a notable lack of comparative analysis on the characteristics of various pathogens identified through NAAT, resulting in inconsistencies among physicians regarding testing decisions and treatment approaches despite the increasing recognition of its importance in recent years.14,15 To address this gap, this study aimed to compare the clinical characteristics of patients with STI detected through NAAT, ultimately providing insights for more consistent clinical management. Furthermore, identifying patients at risk for persistent NAAT positivity during follow-up might help preventing further transmission of STIs. METHODS Study design This study was designed as a retrospective observational cohort study, reviewing clinical data collected from a single secondary care hospital between January 2012 and May 2024, covering the period from the introduction of NAAT in Korea. Adult patients were included if they were diagnosed with at least one STI pathogen (CT, MG, or NG) identified via NAAT in urine or vaginal discharge samples. Cases were excluded if patients failed to return for follow-up after the initial diagnosis or were pregnant at the time of diagnosis. The analysis was conducted in two parts. The first part focused on pathogen-specific comparative analysis, which included only patients with a single pathogen among CT, MG, or NG detected by NAAT. The second part examined factors associated with failure of NAAT clearance by analyzing only patients who underwent at least one follow-up NAAT within three months post-treatment according to guidelines, since differentiating reinfection becomes challenging after three months.6 Data collection Clinical data were extracted from electronic medical records, including age, sex, a history of diabetes mellitus or HIV, presenting symptoms (e.g., discharge and dysuria), and a prior history of STIs—defined as a diagnosis or treatment for an STI within the past two years—based on a previous study.16 Details of initial diagnosis, treatment regimens, follow-up NAAT results, and complications (e.g., epididymitis, prostatitis, urethral stricture, tubo-ovarian abscess, pelvic inflammatory disease, and chronic pelvic pain) were reviewed. Laboratory data included NAAT results for CT, MG, and NG, as well as results from urinalysis, culture tests, and serological analyses. Microbiologic diagnosis Cervical or vaginal swabs, as well as urine samples, were collected and processed according to standardized protocols following manufacturer and laboratory guidelines. All specimens were delivered to the laboratory on the day of collection, and nucleic acid extraction and NAATs were performed within the recommended timeframes to ensure test validity. NAATs were conducted using commercially available real-time PCR kits, Anyplex™ II STI-7 or Anyplex™ II STI-12 (Seegene, Seoul, Korea), both of which are approved for diagnostic use in Korea. Statistical analysis For the pathogen-specific comparisons, a Kruskal-Wallis test was used to compare the three groups (CT, MG, and NG) followed by post-hoc analysis using Bonferroni’s method.17,18 Based on the P value calculated by Bonferroni’s method, additional analyses were conducted using χ2 tests for categorical variables and t-tests for continuous variables. For the analysis of risk factors associated with failure of NAAT clearance, the two groups were compared based on follow-up NAAT results. Categorical variables were analyzed using the χ2 test, while continuous variables were compared using the t-test. Independent risk factors were then identified through multivariate logistic regression. Statistical significance was defined as a P value < 0.05. All analyses were conducted using SPSS version 29 (IBM Corp., Armonk, NY, USA) and R software version 4.3.1 (R Foundation for Statistical Computing, Vienna, Austria, http://www.R-project.org). Ethics statement The study protocol was reviewed and approved by the Institutional Review Board of Seoul Metropolitan Goverment-Seoul National University Boramae Medical Center (approval No. 30-2024-61). Informed consent was waived due to the retrospective nature of the study, which involved no direct patient interaction. All data were anonymized prior to analysis to ensure confidentiality. RESULTS Pathogen-specific characteristics comparisons After excluding cases without follow-up or with co-infections, 500 cases with STIs diagnosed by NAATs were included in the final analysis (Fig. 1), including 269 cases of CT (53.8%), 186 cases of MG (37.2%), and 45 cases of NG (9.0%, Table 1). Among all cases, 80.8% were female, and the median age (interquartile range) was 27.0 (23.0–32.0) years. Post-hoc analysis revealed that the proportion of female patients was significantly higher in CT cases (85.5%) compared to NG cases (64.4%, P = 0.006; Supplementary Fig. 1). HIV co-infection was more prevalent in MG cases (11.8%) than in CT cases (4.5%, P = 0.006). Additionally, viridans group streptococci were significantly more frequently cultured in NG (11.1%) compared to CT (0.4%, P < 0.001) and MG cases (1.1%, P = 0.004). The proportion of symptomatic infections varied, with MG showing the lowest rate (43.0%) compared to CT (60.6%, P < 0.001) and NG (77.8%, P < 0.001). Pyuria was most associated with NG (46.4%), whereas complicated infections were most frequently seen in CT (28.6%). Most complicated infections occurred in women and were identified as pelvic inflammatory disease (97.8%) or tubo-ovarian abscess (3.2%). Flow chart of the study population based on nucleic acid amplification tests. NAAT = nucleic acid amplification test, CT = Chlamydia trachomatis, MG = Mycoplasma genitalium, NG = Neisseria gonorrhoeae. Table 1Clinical characteristics of sexually transmitted infections by causative pathogensVariablesChlamydia trachomatis (n = 269)Mycoplasma genitalium (n = 186)Neisseria gonorrhoeae (n = 45)Total (n = 500)P valueaAge, yr26 (23.0–32.0)27 (24.0–32.0)31 (23.0–43.0)27 (23.0–32.0)0.053Sex, female230 (85.5)145 (78.0)29 (64.4)404 (80.8)0.002Diabetes mellitus1 (0.4)2 (1.1)1 (2.2)4 (0.8)0.378Human immunodeficiency virus infection12 (4.5)22(11.8)4 (8.9)38 (7.6)0.013Prior sexually transmitted infection historyb 27 (10.0)21 (11.3)10 (22.2)58 (11.6)0.061Symptomatic infection163 (60.6)80 (43.0)35 (77.8)278 (55.6)< 0.001Pyuriac 55 (29.9)13 (12.3)13 (46.4)81 (25.5)< 0.001Discharge91 (33.8)56 (30.1)25 (55.6)172 (34.4)0.005Dysuria53 (19.7)31 (16.7)13 (28.9)97 (19.4)0.107Rash11 (4.1)6 (3.2)4 (8.9)21 (4.2)0.330Abdominal pain91 (33.8)13 (7.0)6 (13.3)110 (22.0)< 0.001Complicated infectiond 77 (28.6)10 (5.4)7 (15.6)94 (18.8)< 0.001Multiple pathogense 169 (62.8)120 (64.5)20 (44.4)309 (61.8)0.040NAAT positive of other bacteria Ureaplasma urealyticum 73 (27.1)53 (28.5)8 (17.8)134 (26.8)0.379 Ureaplasma parvum 41 (15.2)43 (23.1)4 (8.9)88 (17.6)0.063 Mycoplasma hominis 46 (17.1)36 (19.4)5 (11.1)87 (17.4)0.004Culture positive91 (33.8)60 (32.3)14 (31.1)165 (33.0)0.977ß-hemolytic streptococci34 (12.6)13 (7.0)2 (4.4)49 (9.8)0.062Viridans group streptococci1 (0.4)2 (1.1)5 (11.1)8 (1.6)< 0.001 Staphylococcus aureus 6 (2.2)10 (5.4)0 (0.0)16 (3.2)0.098Coagulase-negative staphylococci16 (5.9)5 (2.7)1 (2.2)22 (4.4)0.191 Enterococcus faecalis 7 (2.6)6 (3.2)1 (2.2)14 (2.8)0.801Other gram-positive bacteria3 (1.1)1 (0.5)2 (4.4)6 (1.2)0.153 Escherichia coli 12 (4.5)10 (5.4)1 (2.2)23 (4.6)0.099Other gram-negative bacteria5 (1.9)4 (2.2)1 (2.2)10 (2.0)0.894 Candida species9 (3.3)12 (6.5)0 (0.0)21 (4.2)0.154Values are presented as number (%) or median (interquartile range).NAAT = nucleic acid amplification test.aA Kruskal-Wallis test was used to compare the three groups; bPrior sexually transmitted infection history is defined as having been diagnosed with and treated for a sexually transmitted infection within the past two years; cOnly patients who underwent urinalysis were included; dComplicated infection is defined as epididymitis, prostatitis, urethral stricture, tubo-ovarian abscess, pelvic inflammatory disease, and chronic pelvic pain; eCases where other species were detected in NAAT or culture tests were defined as having multiple pathogens. Clinical characteristics of sexually transmitted infections by causative pathogens Values are presented as number (%) or median (interquartile range). NAAT = nucleic acid amplification test. aA Kruskal-Wallis test was used to compare the three groups; bPrior sexually transmitted infection history is defined as having been diagnosed with and treated for a sexually transmitted infection within the past two years; cOnly patients who underwent urinalysis were included; dComplicated infection is defined as epididymitis, prostatitis, urethral stricture, tubo-ovarian abscess, pelvic inflammatory disease, and chronic pelvic pain; eCases where other species were detected in NAAT or culture tests were defined as having multiple pathogens. Risk factors associated with failure of follow-up NAAT clearance A total of 221 cases completed follow-up NAAT within three-months post-treatment (Table 2). Among them, 188 (85.1%) achieved NAAT clearance, while 33 (14.9%) did not. Among the pathogens detected by NAAT, CT was more prevalent in the negative conversion group than in the clearance failure group (negative conversion vs. failure of conversion: 75.5% vs. 54.5%, P = 0.015). In contrast, MG was the most frequently detected pathogen in the clearance failure group (25.0% vs. 63.6%, P < 0.001). While there was no significant difference in the overall rate of symptomatic infections, the proportion of cases reporting dysuria was higher in the clearance failure group (11.2% vs. 24.2%, P = 0.046). Multivariate analysis identified MG infection (adjusted odds ratio [aOR], 6.100; 95% confidence interval [CI], 2.711–13.725; P < 0.001) and symptomatic presentation at diagnosis (aOR, 2.542; 95% CI, 1.103–5.861; P = 0.029) as independent risk factors for failure of NAAT clearance. Analysis of the relationship between antibiotic use and NAAT clearance was limited due to diverse combinations and varying durations (one or two weeks). However, in MG cases, the ratio of macrolide use was significantly higher in the negative conversion group (Supplementary Table 1). Although doxycycline was frequently co-administered with other antibiotics, there were no notable differences in the types or frequencies of co-administered agents between the negative conversion and failure groups. Table 2Factors associated with failure of conversion to a negative result in nucleic acid amplification tests post-treatmentVariablesNegative conversion (n = 188)Failure of conversion (n = 33)Univariate analysisaMultivariate analysisaOR (95% CI)P valueaOR (95% CI)P valueAge, yr25.2 (23.0–30.0)27.0 (24.0–30.0)0.990 (0.946–1.037)0.674Sex, female173 (92.0)27 (81.8)0.390 (0.139–1.093)0.073Diabetes mellitus2 (1.1)1 (3.0)2.906 (0.256–32.998)0.389Human immunodeficiency virus infection1 (0.5)0 (0.0)0.000 (0.000–0.000)1.000Prior sexually transmitted infection historyb 20 (10.6)6 (18.2)1.867 (0.688–5.068)0.221PathogenChlamydia trachomatis 142 (75.5)18 (54.5)0.389 (0.182–0.833)0.015Mycoplasma genitalium 47 (25.0)21 (63.6)5.250 (2.401–11.479)< 0.0016.100 (2.711–13.725)< 0.001Neisseria gonorrhoeae 22 (11.7)2 (6.1)0.487 (0.109–2.176)0.346Multiple pathogensc 137 (72.9)21 (63.6)0.651 (0.299–1.419)0.281Symptomatic infection96 (51.1)22 (66.7)1.917 (0.880–4.174)0.1012.542 (1.103–5.861)0.029Pyuriad 35 (24.6)9 (32.1)1.448 (0.601–3.492)0.410Discharge56 (29.8)12 (36.4)1.347 (0.620–2.924)0.451Dysuria21 (11.2)8 (24.2)2.545 (1.018–6.363)0.046Rash8 (4.3)0 (0.0)0.000 (0.000–0.000)0.999Abdominal pain37 (19.7)7 (21.2)1.099 (0.443–2.726)0.839Complicated infectione 32 (17.0)6 (18.2)1.083 (0.414–2.838)0.871Follow-up interval, day43.0 (35.5–49.0)44.0 (31.0–57.0)1.015 (0.991–1.039)0.217Values are presented as number (%) or median (interquartile range).OR = odds ratio, CI = confidence interval, aOR = adjusted odds ratio.aCategorical variables were analyzed using the χ2 test, while continuous variables were compared using the t-test. To conduct multivariate analysis, independent risk factors were identified via logistic regression; bPrior sexually transmitted infection history is defined as having been diagnosed with and treated for a sexually transmitted infection within the past two years; cCases where other species were detected in nucleic acid amplification test or culture tests were defined as having multiple pathogens; dOnly patients who underwent urinalysis were included; eComplicated infection is defined as epididymitis, prostatitis, urethral stricture, tubo-ovarian abscess, pelvic inflammatory disease, and chronic pelvic pain. Factors associated with failure of conversion to a negative result in nucleic acid amplification tests post-treatment Values are presented as number (%) or median (interquartile range). OR = odds ratio, CI = confidence interval, aOR = adjusted odds ratio. aCategorical variables were analyzed using the χ2 test, while continuous variables were compared using the t-test. To conduct multivariate analysis, independent risk factors were identified via logistic regression; bPrior sexually transmitted infection history is defined as having been diagnosed with and treated for a sexually transmitted infection within the past two years; cCases where other species were detected in nucleic acid amplification test or culture tests were defined as having multiple pathogens; dOnly patients who underwent urinalysis were included; eComplicated infection is defined as epididymitis, prostatitis, urethral stricture, tubo-ovarian abscess, pelvic inflammatory disease, and chronic pelvic pain. Comparison of patients with gonococcal and non-gonococcal infections When comparing gonococcal with non-gonococcal infections (CT and MG), cases with non-gonococcal infections were significantly more likely to be female (gonococcal vs. non-gonococcal: 64.4% vs. 82.4%, P = 0.006; Supplementary Table 2). Additionally, gonococcal infections had a higher prevalence of prior STI history (22.2% vs. 10.5%, P = 0.037). Also, symptomatic infections were significantly more common in gonococcal cases (77.8% vs. 53.4%, P = 0.003), particularly pyuria (46.4% vs. 23.4%, P = 0.010) and discharge (55.6% vs. 32.3%, P = 0.003). Comparison of female and male patients The median age was younger in female patients than in male patients (female vs. male: 26.0 vs. 31.0, P < 0.001; Supplementary Table 3). HIV co-infection was significantly more frequent in males (1.0% vs. 35.4%, P < 0.001). The detection of multiple pathogens was significantly higher in female patients (73.8% vs. 11.5%, P < 0.001), which was primarily attributable to culture results. Additionally, the prevalence of accompanying abdominal pain (27.0% vs. 1.0%, P < 0.001) and complicated infections (22.8% vs. 2.1%, P < 0.001) was significantly higher in females. DISCUSSION Our study found that most STI patients diagnosed by NAAT were sexually active young adults, predominantly female. Among the three pathogens analyzed, CT infections had the highest complication rate, while NG infections were the most symptomatic, often presenting with pyuria and discharge, consistent with a previous study.19 MG had the lowest proportion of symptomatic cases, but was a major risk factor for NAAT clearance failure. Based on previous studies, CT infection is well known to cause severe reproductive tract complications in women, with pelvic inflammatory disease occurring in up to 30% of cases.20,21 Similarly, in our study, 28.6% of CT infections were associated with complications (33.0% among women), mainly as pelvic inflammatory disease or tubo-ovarian abscess. In contrast, NG infections—particularly penile urethral gonorrhea—tended to present with symptoms, consistent with prior studies showing high rates of dysuria and urethral discharge in men.22,23 MG had a high asymptomatic detection rate (57.0%) and significantly lower rates of pyuria and complicated infections; however, post-treatment NAAT clearance was poor (69.1%). This aligns with previous studies linking MG persistence to increasing resistance to macrolides and fluoroquinolones.7 The higher negative conversion rate in MG cases treated with antibiotic regimens that included macrolides suggests that macrolide resistance may not yet be highly prevalent in Korea. However, since approximately 30% of patients did not achieve NAAT clearance, the guideline-recommended combination therapy, such as the doxycycline–moxifloxacin regimen, should be actively considered.8,24,25 Concurrently, efforts to improve guideline dissemination are warranted.26 Since MG cannot be cultured, diagnosis relies on NAATs, making antibiotic susceptibility testing impractical in most institutions. This diagnostic limitation necessitates empirical treatment, which often results in poor eradication rates and repeated treatment courses, complicating MG management.27 Indeed, the global prevalence of resistance-conferring genetic mutations in MG has been steadily rising, from 10% before 2010 to over 50% in 2016–2017,13,28 underscoring the urgent need for effective antibiotic resistance monitoring methods. The implementation of commercially available antibiotic resistance genetic testing may help to guide targeted therapy.29 Beyond optimizing therapeutic regimens, future studies should focus on investigating the long-term prognosis of patients who fail to achieve NAAT clearance, which could also help reduce unnecessary antibiotic exposure. Previous studies have identified Enterococcus faecalis, viridans group streptococci, Escherichia coli, and staphylococci as common cultured pathogens in vaginitis patients.30 In our study, co-infections were observed in 61.8% of cases, with 33.0% involving culture-detectable bacteria, and viridans group streptococci frequently detected in NG infections. The presence of symptoms and pyuria suggests an inflammatory response in the genital tract, supported by both experimental models and clinical data indicating an association with dysbiosis and symptomatic inflammation.31,32 Further research is needed to explore whether vaginal lactobacilli supplementation could help counteract dysbiosis in symptomatic patients with STI.33 This study has several limitations. Its retrospective design, and reliance on physicians’ judgement for assessing complicated infections may compromise the generalizability of the findings. Additionally, co-detection of multiple pathogens, observed in 61.8% of cases, made it challenging to determine the primary causative organism. Due to follow-up PCR being performed in less than half of the total cases, the reduced sample size in the NAAT follow-up analysis may have led to decreased statistical power and potential selection bias. Nevertheless, this study provides valuable insights into the distinct clinical characteristics of STI pathogens (CT, MG, and NG) diagnosed via NAAT, providing valuable insights into their differing presentations. Variability in antibiotic treatment further complicates analysis, particularly for MG, where differences in drug choice (fluoroquinolones, macrolides, and doxycycline with or without combination), and treatment duration hinder a standardized approach. This heterogeneity made quantitative assessment of treatment efficacy unfeasible and underscores inconsistencies in guideline implementation.6 Given the rising resistance of MG, additional controlled trials are needed to establish optimal treatment strategies.34 Lastly, some asymptomatic cases involved sexual assault victims and individuals diagnosed through partner notification. While treatment decisions for these patients may not be based on symptomatology alone, appropriate therapy remains crucial for preventing further transmission and long-term complications.11,35 In conclusion, this study underscores key differences in the clinical manifestations of CT, MG, and NG infections. CT exhibited the highest prevalence of complicated infections, while NG was more frequently associated with symptomatic presentations. MG also emerged as a major risk factor for NAAT clearance failure in Korean patients, emphasizing the need for antimicrobial resistance monitoring and further research to determine optimal retreatment strategies. Footnotes Disclosure: The authors have no potential conflicts of interest to disclose. Author Contributions: Conceptualization: Shin DH.Data curation: Son JS, Shin DH.Formal analysis: Son JS, Shin DH.Investigation: Son JS, Shin DH.Methodology: Shin DH, Kim N.Project administration: Shin DH.Supervision: Shin DH.Visualization: Son JS, Shin DH.Writing - original draft: Son JS, Kim N.Writing - review & editing: Kim N, Oh HS, Park SW, Shin DH. Conceptualization: Shin DH. Conceptualization: Shin DH. Data curation: Son JS, Shin DH. Data curation: Son JS, Shin DH. Formal analysis: Son JS, Shin DH. Formal analysis: Son JS, Shin DH. Investigation: Son JS, Shin DH. Investigation: Son JS, Shin DH. Methodology: Shin DH, Kim N. Methodology: Shin DH, Kim N. Project administration: Shin DH. Project administration: Shin DH. Supervision: Shin DH. Supervision: Shin DH. Visualization: Son JS, Shin DH. Visualization: Son JS, Shin DH. Writing - original draft: Son JS, Kim N. Writing - original draft: Son JS, Kim N. Writing - review & editing: Kim N, Oh HS, Park SW, Shin DH. Writing - review & editing: Kim N, Oh HS, Park SW, Shin DH. SUPPLEMENTARY MATERIALS Supplementary Table 1 Comparison of antibacterials used by causative pathogens based on follow-up nucleic acid amplification test clearance Supplementary Table 2 Comparison of patients with gonococcal and non-gonococcal infections Supplementary Table 3 Comparison of female and male patients Supplementary Fig. 1 Comparison by causative bacteria of sexually transmitted infections–post-hoc analysis. Post-hoc analysis with Bonferroni’s method was performed, followed by χ2 tests for categorical variables and t-tests for continuous variables based on the calculated P values. References Associated Data Supplementary Materials Supplementary Table 1 Comparison of antibacterials used by causative pathogens based on follow-up nucleic acid amplification test clearance Supplementary Table 2 Comparison of patients with gonococcal and non-gonococcal infections Supplementary Table 3 Comparison of female and male patients Supplementary Fig. 1 Comparison by causative bacteria of sexually transmitted infections–post-hoc analysis. Post-hoc analysis with Bonferroni’s method was performed, followed by χ2 tests for categorical variables and t-tests for continuous variables based on the calculated P values.